• LAST PRICE
    7.7500
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    6.9000/ 1
  • Ask / Lots
    9.5000/ 4
  • Open / Previous Close
    0.0000 / 7.7500
  • Day Range
    ---
  • 52 Week Range
    Low 5.7500
    High 21.6800
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 7.92
TimeVolumeKNTE
09:32 ET32918.15
09:33 ET14158.21
09:39 ET5858.22
09:42 ET1008.16
09:53 ET16408.06
09:55 ET3008.08
10:04 ET7118.22
10:08 ET5008.31
10:18 ET2008.3
10:20 ET5008.1
10:26 ET2008.095
10:27 ET6008.04
10:29 ET2007.985
10:36 ET1007.95
10:44 ET1007.93
11:25 ET3008.13
11:32 ET2008.04
11:34 ET1008.05
11:36 ET8348.02
11:45 ET2008
11:50 ET2007.97
11:59 ET1007.94
12:06 ET5007.92
12:10 ET7507.8648
12:14 ET1007.76
12:15 ET2957.8685
12:19 ET1007.69
12:26 ET2007.835
12:28 ET4327.84
12:33 ET1008
12:44 ET1007.905
01:08 ET2007.96
01:24 ET3007.94
01:29 ET13197.88
01:33 ET8617.75
01:36 ET13007.79
01:38 ET1007.81
01:40 ET2297.77
01:42 ET5007.77
01:54 ET4007.69
01:56 ET1007.64
02:00 ET1007.68
02:03 ET1007.66
02:05 ET1007.65
02:12 ET5007.65
02:25 ET1007.66
02:30 ET1007.66
02:34 ET2007.66
02:39 ET2007.64
02:48 ET1007.65
02:52 ET6007.77
02:56 ET1007.7925
02:57 ET5007.73
03:08 ET9017.75
03:15 ET1007.68
03:17 ET1007.68
03:21 ET1007.64
03:24 ET3527.68
03:26 ET3007.7
03:32 ET1007.69
03:35 ET8507.69
03:42 ET5627.6854
03:53 ET1007.67
03:57 ET7217.71
04:00 ET59717.75
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKNTE
Kinnate Biopharma Inc
342.3M
-3.1x
---
United StatesOMGA
Omega Therapeutics Inc
338.7M
-3.6x
---
United StatesCBAY
Cymabay Therapeutics Inc
334.5M
-3.2x
---
United StatesOCGN
Ocugen Inc
332.7M
-4.3x
---
United StatesPEPG
PepGen Inc
330.8M
-5.2x
---
United StatesOABI
OmniAB Inc
330.1M
-10.7x
---
As of 2022-12-02

Company Information

Kinnate Biopharma Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its products candidate include KIN-2787, KIN-3248 and KIN004. The KIN-2787 is a small molecule kinase inhibitor targeting specific classes of BRAF kinase alterations that characterize subsets of lung cancer, melanoma and other solid tumors. The Company has initiated a Phase I clinical trial for KIN-2787 (KN-8701). KIN-3248 is a small-molecule kinase inhibitor targeting cancer-associated alterations in FGFR2 and FGFR3 genes. KIN-3248 address the initial alteration and clinically-observed and predicted mutations in FGFR2 fusion gene-positive intrahepatic cholangiocarcinoma and FGFR3-altered ulcerative colitis. It is also developing a CDK12 inhibitor candidate to target the treatment of ovarian carcinoma, metastatic castration-resistant prostate cancer and triple-negative breast cancer.

Contact Information

Headquarters
11975 El Camino Real, Ste 101, Suite 101SAN DIEGO, CA, United States 92130
Phone
858-299-4699
Fax
302-655-5049

Executives

Independent Chairman of the Board
Dean Mitchell
President, Chief Executive Officer, Director
Nima Farzan
Chief Financial Officer, Executive Vice President - Corporate Development
Neha Krishnamohan
Chief Operating Officer, General Counsel
Mark Meltz
Chief Medical Officer
Richard Williams

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$342.3M
Revenue (TTM)
$0.00
Shares Outstanding
44.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.52
Book Value
$7.28
P/E Ratio
-3.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.